PATENT CLAIM ANALYSIS

Application Number: 15961419
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-05
Patent Classification: ["514", "253130"]

Abstract:
Treatment with 2-amino substituted nicotinamides or their salts ameliorates the cognitive and motor dysfunction associated with Angelman Syndrome (AS).

Claim (Index 2):
The method of  claim 1  wherein the cognitive deficiency tested in laboratory models is a decrease in novel place recognition (NPR), a decrease in novel object recognition (NOR), a decrease in object in place (OiP) preference, a decrease in recognition of temporal order (TO) and/or an enhanced reaction to fear, and is tested in humans by the CogScreen test.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 91.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15895881', '15702162', '15004218', '15869672', '13361720']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7392553861669614
- 35 USC 102 Novelty (BERT): 0.5081566994534199
- Combined Prediction Score: 0.7161455174956073
- Mean Citation Score: 149.459582
- Max Citation Score: 217.80348
- Similarity Product: 132.51033623873235

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test